Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Status:
Completed
Trial end date:
2021-10-05
Target enrollment:
Participant gender:
Summary
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and
tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction,
consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple
myeloma patients.